Terns Pharmaceuticals Inc (TERN) Return on Investment ROI from the fourth quarter of 2025 to fourth quarter of 2024 and for the year 2025, average high and low, overall ranking from Dec 31 2025 to Dec 31 2024 - CSIMarket
Terns Pharmaceuticals Inc's ROI from its fourth quarter of 2025 to the fourth quarter of 2024 and 5 Year Period
Return on Investment, Quarterly Results, Trends, Rankings, Statistics
What is Terns Pharmaceuticals Inc's ROI in the fourth quarter of 2025?
Terns Pharmaceuticals Inc recorded a cumulative net loss of $-96 million during 12 months ending in the fourth quarter of 2025, resulting in a negative return on investment (ROI) of -19.93%.
Within the Healthcare sector 315 other companies had a higher return on investment. While Return on investment, overall ranking has progressed in the Dec 31 2025 quarter, so far to 3031, from total ROI ranking in the third quarter of 2025 at 3249.
In the dynamic landscape of biopharmaceuticals, where innovation and talent are pivotal to success, Terns Pharmaceuticals, Inc. (Nasdaq: TERN), located in Foster City, California, is making notable strides not only in its clinical programs but also in its strategic human resource initiatives. On April 1, 2025, Terns announced the granting of equity inducement awards to two new employees, a move that underscores the company s commitment to attracting top talent in the competitive biopharmaceutical sector. This initiative, approved by the Compensation Committee of the Board of Directors, aligns with the provisions of Nasdaq Listing Rule 5635(c)(4) and demonstrates Terns proactive stance in enhancing its workforce capabilities as it advances its clinical programs focused on serious diseases, including obesity and cancer.The equity inducement awards are part of Terns Pharmaceuticals 2022 Employment Inducement Award Plan, which aims to incentivize high-caliber professionals to join the company amidst a period of growth and innovation. By offering equity awards as a material inducement for employment acceptance, Terns not only enhances its recruitment strategy but also aligns the interests of its employees with the company’s long-term success, fostering a culture of shared ownership and collaboration.
The landscape of biopharmaceuticals is rapidly evolving, as innovative compounds and methodologies are emerging to address complex health challenges. Terns Pharmaceuticals is making significant strides with two of its key candidates: TERN-601, a once-daily oral GLP-1 receptor agonist for obesity management, and TERN-701, an allosteric BCR-ABL inhibitor targeting certain cancers. Recently, the company announced promising results from Phase 1 clinical trials for both products, suggesting they may soon offer new hope for patients grappling with obesity and oncology-related concerns. Positive Phase 1 Results with TERN-601 for Obesity Management Terns Pharmaceuticals has unveiled results from a Phase 1 clinical trial that investigated TERN-601, a novel GLP-1 receptor (GLP-1R) agonist designed for the treatment of obesity. The trial has shown statistically significant weight loss among participants, achieving a mean reduction of up to 5.5% over 28 days, with a placebo-adjusted weight loss of 4.9%. These results underscore the potential of TERN-601 as a robust candidate for addressing one of the world’s most prevalent health issues obesity.
Terns Pharmaceuticals Appoints Biotech Executive Elona Kogan as Chief Legal Officer and Announces Upcoming CFO Transition FOSTER CITY, Calif., July 29, 2024 - Terns Pharmaceuticals, a leading clinical-stage biopharmaceutical company focused on developing small-molecule product candidates to tackle critical diseases such as oncology and obesity, announced today the appointment of Elona Kogan, Esq., as their new Chief Legal Officer. The company also revealed that they will soon undergo a transition in the role of Chief Financial Officer (CFO). These developments showcase Terns commitment to enhancing their leadership team and positioning the company for sustained success. Elona Kogan s appointment marks a significant milestone in Terns Pharmaceuticals journey. Ms. Kogan brings extensive experience in the biotechnology sector, having effectively guided several companies through transformative growth and strategic transactions. Her expertise in legal affairs and her profound understanding of the biotech industry make her an excellent fit for Terns, as the company aims to advance their pipeline of innovative therapies.
Terns Pharmaceuticals Undergoes Leadership Changes as it Navigates the Path to Addressing Serious Diseases FOSTER CITY, Calif., May 08, 2024 - Terns Pharmaceuticals, Inc. (Nasdaq: TERN), a clinical-stage biopharmaceutical company with a focus on developing small-molecule product candidates to tackle severe diseases such as oncology and obesity, has announced significant leadership changes. The company has appointed Scott Harris as the new Chief Development Officer (CDO), effective May 28, 2024. Concurrently, the current President and Head of Research and Development, Dr. Erin Quirk, will be leaving the position on June 3, 2024, to explore alternative opportunities. Terns Pharmaceuticals has been at the forefront of cutting-edge research and development, striving to address some of today s most challenging health conditions. The introduction of Scott Harris as CDO marks another milestone in the company s growth and commitment to advancing its product portfolio further.
Financial Statements
Terns Pharmaceuticals Inc's IV. Quarter Investments
Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com
Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.
